Compare LMB & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | XERS |
|---|---|---|
| Founded | 1901 | 2005 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2014 | 2021 |
| Metric | LMB | XERS |
|---|---|---|
| Price | $72.72 | $6.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $116.67 | $10.83 |
| AVG Volume (30 Days) | 310.6K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.68 | ★ 100.00 |
| EPS | ★ 0.36 | 0.01 |
| Revenue | ★ $646,804,000.00 | $49,590,000.00 |
| Revenue This Year | $15.96 | $34.37 |
| Revenue Next Year | $5.90 | $22.86 |
| P/E Ratio | ★ $207.75 | $636.50 |
| Revenue Growth | 24.68 | ★ 142.67 |
| 52 Week Low | $65.08 | $4.30 |
| 52 Week High | $154.04 | $10.08 |
| Indicator | LMB | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 51.90 |
| Support Level | $71.40 | $6.26 |
| Resistance Level | $85.38 | $6.41 |
| Average True Range (ATR) | 6.95 | 0.28 |
| MACD | -2.73 | 0.00 |
| Stochastic Oscillator | 3.91 | 28.50 |
Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.